Polo L, Segalla A, Jori G, Bocchiotti G, Verna G, Franceschini R, Mosca R, De Filippi P G
Dipartimento di Biologia, Università di Padova, Italy.
Cancer Lett. 1996 Dec 3;109(1-2):57-61. doi: 10.1016/s0304-3835(96)04409-6.
131I-Zn(II)-phthalocyanine (ZnPc) incorporated into unilamellar liposomes has been systemically injected to mice bearing a transplanted MS-2 fibrosarcoma. Biodistribution studies show that the pharmacokinetic behaviour of 131I-ZnPc is very similar to that defined for the parent molecule ZnPc including a serum half-life of ca. 12 h, a high recovery from liver and spleen and minimal accumulation in kidney and brain. The most important pharmacokinetic parameter is represented by the high tumour/ muscle ratio of 131I-ZnPc concentration (ca. 9 at 24 h post-injection). These results suggest the possible use of the radiolabelled derivative for a real-time non-invasive monitoring of the ZnPc concentration in the tumour and peritumoural tissue during photodynamic therapy.
